

Supplementary Table 1: Summary of the economic analysis results for different scenarios

Higher usual care cost (£98.7 per patient per month) scenario				
	Usual care	STS HM	STS HH	TM
Total costs				
Including Home-HF ¹²	£8,861	£8,965	£9,574	£9,437
Excluding Home-HF ¹²	£8,861	£9,087	£9,658	£9,665
Total QALYs				
Including Home-HF ¹²	2.4137	2.3633	2.4950	2.4944
Excluding Home-HF ¹²	2.4137	2.4043	2.5230	2.5847
ICERs				
Including Home-HF ¹²		Dominated	£228,035 ^a	£7,133
Excluding Home-HF ¹²		Dominated	Extendedly dominated	£4,703 ^a
Probability of cost-effectiveness				
Including Home-HF ¹²	4%	19%	35%	41%
Excluding Home-HF ¹²	1%	7%	19%	73%
Lower cost (£133.5 per patient per month) of TM during office hours scenario				
	Usual care	STS HM	STS HH	TM
Total costs				
Including Home-HF ¹²	£8,478	£8,965	£9,574	£9,211
Excluding Home-HF ¹²	£8,478	£9,087	£9,658	£9,435
Total QALYs				
Including Home-HF ¹²	2.4137	2.3633	2.4950	2.4944
Excluding Home-HF ¹²	2.4137	2.4043	2.5230	2.5847
ICERs				
Including Home-HF ¹²		Dominated	£605,112 ^a	£9,080
Excluding Home-HF ¹²		Dominated	Extendedly dominated	£5,595 ^a
Probability of cost-effectiveness				
Including Home-HF ¹²	6%	18%	33%	44%
Excluding Home-HF ¹²	1%	6%	16%	77%

STS HM, structured telephone support via human to machine interface; STS HH, structured telephone support via human to human contact; TM, telemonitoring; QALYs, quality adjusted life years; ICERs, incremental cost-effectiveness ratios

^a last strategy in the cost-effectiveness frontier

Higher cost (£215 per patient per month) of TM during office hours scenario

	Usual care	STS HM	STS HH	TM
Total costs				
Including Home-HF ¹²	£8,478	£8,965	£9,574	£9,652
Excluding Home-HF ¹²	£8,478	£9,087	£9,658	£9,884
Total QALYs				
Including Home-HF ¹²	2.4137	2.3633	2.4950	2.4944
Excluding Home-HF ¹²	2.4137	2.4043	2.5230	2.5847
ICERs				
Including Home-HF ¹²		Dominated	£13,473 ^a	Dominated
Excluding Home-HF ¹²		Dominated	Extendedly dominated	£8,223 ^a
Probability of cost-effectiveness				
Including Home-HF ¹²	7%	20%	37%	37%
Excluding Home-HF ¹²	1%	8%	23%	68%

Higher cost (£192 per patient per month) of STS HH scenario

	Usual care	STS HM	STS HH	TM
Total costs				
Including Home-HF ¹²	£8,478	£8,965	£9,645	£9,437
Excluding Home-HF ¹²	£8,478	£9,087	£9,729	£9,665
Total QALYs				
Including Home-HF ¹²	2.4137	2.3633	2.4950	2.4944
Excluding Home-HF ¹²	2.4137	2.4043	2.5230	2.5847
ICERs				
Including Home-HF ¹²		Dominated	£346,341 ^a	£11,873
Excluding Home-HF ¹²		Dominated	Extendedly dominated	£6,942 ^a
Probability of cost-effectiveness				
Including Home-HF ¹²	6%	19%	34%	41%
Excluding Home-HF ¹²	1%	7%	18%	74%

STS HM, structured telephone support via human to machine interface; STS HH, structured telephone support via human to human contact; TM, telemonitoring; QALYs, quality adjusted life years; ICERs, incremental cost-effectiveness ratios

^a last strategy in the cost-effectiveness frontier

Lower cost (£175 per patient per month) of STS HH scenario

	Usual care	STS HM	STS HH	TM
Total costs				
Including Home-HF ¹²	£8,478	£8,965	£9,553	£9,437
Excluding Home-HF ¹²	£8,478	£9,087	£9,636	£9,665
Total QALYs				
Including Home-HF ¹²	2.4137	2.3633	2.4950	2.4944
Excluding Home-HF ¹²	2.4137	2.4043	2.5230	2.5847
ICERs				
Including Home-HF ¹²		Dominated	£193,206 ^a	£11,873
Excluding Home-HF ¹²		Dominated	Extendedly dominated	£6,942 ^a
Probability of cost-effectiveness				
Including Home-HF ¹²	6%	19%	35%	40%
Excluding Home-HF ¹²	1%	7%	20%	72%

STS HM, structured telephone support via human to machine interface; STS HH, structured telephone support via human to human contact; TM, telemonitoring; QALYs, quality adjusted life years; ICERs, incremental cost-effectiveness ratios

^a last strategy in the cost-effectiveness frontier